| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5286002
Max Phase: Preclinical
Molecular Formula: C40H48NO11P
Molecular Weight: 749.79
Associated Items:
Representations
Canonical SMILES: CCOP(=O)(OCC)C(Nc1ccc(CC(=O)OCCOc2cc(/C=C\c3cc(OC)c(OC)c(OC)c3)ccc2OC)cc1)c1cccc(OC)c1
Standard InChI: InChI=1S/C40H48NO11P/c1-8-51-53(43,52-9-2)40(31-11-10-12-33(27-31)44-3)41-32-18-15-29(16-19-32)26-38(42)50-22-21-49-35-23-28(17-20-34(35)45-4)13-14-30-24-36(46-5)39(48-7)37(25-30)47-6/h10-20,23-25,27,40-41H,8-9,21-22,26H2,1-7H3/b14-13-
Standard InChI Key: IDBPZWFHFXNHLJ-YPKPFQOOSA-N
Associated Targets(Human)
HepG2 (196354 Activities)
HT-29 (80576 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
A549 (127892 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MGC-803 (6426 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
L02 (4864 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MMP2 Tchem Matrix metalloproteinase-2 (6627 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MMP3 Tchem Matrix metalloproteinase 3 (3433 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
MMP9 Tchem Matrix metalloproteinase 9 (6779 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 749.79 | Molecular Weight (Monoisotopic): 749.2965 | AlogP: 8.44 | #Rotatable Bonds: 21 |
| Polar Surface Area: 129.24 | Molecular Species: NEUTRAL | HBA: 12 | HBD: 1 |
| #RO5 Violations: 3 | HBA (Lipinski): 12 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 3 |
| CX Acidic pKa: 12.64 | CX Basic pKa: 0.25 | CX LogP: 6.90 | CX LogD: 6.90 |
| Aromatic Rings: 4 | Heavy Atoms: 53 | QED Weighted: 0.04 | Np Likeness Score: -0.36 |
References
| 1. Huang X, Chen Y, Zhong W, Liu Z, Zhang H, Zhang B, Wang H.. (2022) Novel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment., 244 [PMID:36252396] [10.1016/j.ejmech.2022.114817] |
Source
Source(1):